0 false false false false false false false false false false true false false false false false false No description of principal activity 2024-06-01 Sage Accounts Production Advanced 2025 - FRS102_2025 xbrli:pure xbrli:shares iso4217:GBP 09607843 2024-06-01 2025-05-31 09607843 2025-05-31 09607843 2024-05-31 09607843 2023-06-01 2024-05-31 09607843 2024-05-31 09607843 2023-05-31 09607843 bus:Director1 2024-06-01 2025-05-31 09607843 core:WithinOneYear 2025-05-31 09607843 core:WithinOneYear 2024-05-31 09607843 core:RetainedEarningsAccumulatedLosses 2025-05-31 09607843 core:RetainedEarningsAccumulatedLosses 2024-05-31 09607843 bus:SmallEntities 2024-06-01 2025-05-31 09607843 bus:AuditExempt-NoAccountantsReport 2024-06-01 2025-05-31 09607843 bus:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 09607843 bus:CompanyLimitedByGuarantee 2024-06-01 2025-05-31 09607843 bus:FullAccounts 2024-06-01 2025-05-31
COMPANY REGISTRATION NUMBER: 09607843

GENOME SCIENCE

Company Limited by Guarantee

FILLETED UNAUDITED FINANCIAL STATEMENTS

31 May 2025

GENOME SCIENCE

COMPANY LIMITED BY GUARANTEE

STATEMENT OF FINANCIAL POSITION

31 May 2025

| 2025 | 2024
Note | £ | £ | £

Current assets

Debtors | 5 | 103 |  | 103
Cash at bank and in hand | 49,471 |  | 49,471
| --------- |  | ---------
| 49,574 |  | 49,574

Creditors: amounts falling due within one year | 6 | 1,080 |  | 1,080
| --------- |  | ---------
Net current assets |  | 48,494 | 48,494
|  | --------- | ---------
Total assets less current liabilities |  | 48,494 | 48,494
|  | --------- | ---------
Net assets |  | 48,494 | 48,494
|  | --------- | ---------

Capital and reserves

Profit and loss account |  | 48,494 | 48,494
|  | --------- | ---------
Members funds |  | 48,494 | 48,494
|  | --------- | ---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 May 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

GENOME SCIENCE

COMPANY LIMITED BY GUARANTEE

STATEMENT OF FINANCIAL POSITION (continued)

31 May 2025
These financial statements were approved by the board of directors and authorised for issue on 25 February 2026 , and are signed on behalf of the board by:

Dr N J Loman |
Director |

Company registration number: 09607843

GENOME SCIENCE

COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS

YEAR ENDED 31 MAY 2025
1. General information
The company is a private company limited by guarantee, registered in England and Wales. The address of the registered office is 168 Church Road, Hove, BN3 2DL, East Sussex.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
No material uncertainties, that may cast significant doubt about the ability of the company to continue as a going concern, have been identified by the director.
The directors consider that the uncertainty caused in the company's industry as a result of Coronavirus and the restrictions put in place by the government should not materially affect the company's ability to continue as a going concern.
The company may take advantage of the support packages offered by the government, as appropriate and will continue to review and monitor costs as the situation develops.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Financial instruments
Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
4. Company limited by guarantee
The company is limited by guarantee with no share capital. Any surplus from the activities of the company shall in due course be applied in the carrying out of the objectives.
5. Debtors

| 2025 | 2024
| £ | £
Other debtors | 103 | 103
| ---- | ----

6. Creditors: amounts falling due within one year

| 2025 | 2024
| £ | £
Other creditors | 1,080 | 1,080
| ------- | -------

7. Related party transactions
No transactions with related parties were undertaken such as are required to be disclosed under FRS 102 Section 1A.